GLP-3 Reta 16mg adjustable dose pen by Porta Biologico. Triple GLP-1, GIP, and glucagon receptor agonist, entry level concentration. Lab tested, discreetly shipped across Canada. Intended for research purposes only.
Format16mg
ConcentrationAdjustable Dosage Pen
Pack Size Selected: Single Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 Reta is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. Porta Biologico’s 16mg adjustable dose pen delivers this triple receptor agonist at a lower total concentration than Porta Biologico’s 30mg pen presentation. Matching the entry level concentration point already established by F40 Biotech’s 16mg adjustable dose pen, and providing researchers with a second manufacturer option at this accessible concentration tier.
The 16mg format serves as the lowest concentration adjustable pen option across CSD’s GLP-3 triple incretin agonist range, suited to researchers initiating triple incretin agonist research, conducting initial dose response characterization, or requiring a lower total compound commitment before progressing to higher concentration presentations. The adjustable dose mechanism allows precise dose increments to be dialed from the 16mg total supply without reconstitution preparation, combining administration convenience with titration flexibility across the protocol timeline.
The triple receptor mechanism remains consistent regardless of manufacturer or concentration; GLP-1 receptor activation driving glucose dependent insulin secretion and satiety signaling, GIP receptor activation contributing complementary insulinotropic and adipose tissue metabolic effects, and glucagon receptor co activation adding hepatic glucose regulation, thermogenic energy expenditure, and lipolytic activity. This synergistic three pathway response distinguishes triple incretin agonism from CSD’s dual GIP/GLP-1 agonist listings and the pure GLP-1 selectivity of Semaglutide.
Porta Biologico formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s adjustable dose GLP-3 pen range now spans F40 Biotech at 16mg and 40mg, alongside Porta Biologico at 16mg and 30mg, giving researchers manufacturer and concentration flexibility at the entry level dose tier from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
